A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The hepatopulmonary syndrome (HPS)and pre-HPS is a disease seen in patients with chronic
liver disease, whereby patients develop dilations in the blood vessels of the lungs,
resulting in low oxygen levels and shortness of breath.
In this study, each HPS and pre-HPS subject will be treated with a commonly used antibiotic
called "norfloxacin" (approved for use in the treatment of gonorrhea, prostatitis and urinary
tract infections) for a 4-week period. In order to ensure that any observed improvement was
indeed due to norfloxacin, each subject will also be treated with a separate 4-week course of
an identical placebo. There will also be a 4 week wash-out period (no study
medication/placebo) between the 2 courses of treatment.
The primary aim of the study will be to measure improvements in oxygen levels while on
norfloxacin, although a number of secondary parameters will also be followed.
Phase:
Phase 2
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto